Trevi Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Trevi Therapeutics, Inc. (TRVI) reported Net Income (Loss) Available to Common Stockholders, Basic of -$32.76 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-25.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2021-03-25
- Trevi Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2020-12-31 was -$9.52M.
- Trevi Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2020-09-30 was -$7.38M.
- Trevi Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2020-06-30 was -$7.38M.
- Trevi Therapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2020-03-31 was -$8.47M.
- Trevi Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2020 was -$32.76M.
- Trevi Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2019 was -$26.75M.
- Trevi Therapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2018 was -$25.58M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$9.52M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$16.90M derived: sum of 2 quarters · filed 2021-03-25 | -$24.29M derived: sum of 3 quarters · filed 2021-03-25 | -$32.76M 10-K · filed 2021-03-25 |
| 2020-09-30 | -$7.38M 10-Q · filed 2020-11-12 | -$14.76M derived: sum of 2 quarters · filed 2020-11-12 | -$23.23M 10-Q · filed 2020-11-12 | -$29.77M derived: sum of 4 quarters · filed 2021-03-25 |
| 2020-06-30 | -$7.38M 10-Q · filed 2020-08-13 | -$15.86M 10-Q · filed 2020-08-13 | -$22.39M derived: sum of 3 quarters · filed 2021-03-25 | -$29.76M derived: sum of 4 quarters · filed 2021-03-25 |
| 2020-03-31 | -$8.47M 10-Q · filed 2020-05-07 | -$15.01M derived: sum of 2 quarters · filed 2021-03-25 | -$22.38M derived: sum of 3 quarters · filed 2021-03-25 | -$29.07M derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-12-31 | -$6.54M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$13.90M derived: sum of 2 quarters · filed 2021-03-25 | -$20.60M derived: sum of 3 quarters · filed 2021-03-25 | -$26.75M 10-K · filed 2021-03-25 |
| 2019-09-30 | -$7.37M 10-Q · filed 2020-11-12 | -$14.06M derived: sum of 2 quarters · filed 2020-11-12 | -$20.22M 10-Q · filed 2020-11-12 | -$27.57M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | -$6.70M 10-Q · filed 2020-08-13 | -$12.85M 10-Q · filed 2020-08-13 | -$20.20M derived: sum of 3 quarters · filed 2020-08-13 | -$27.32M derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | -$6.15M 10-Q · filed 2020-05-07 | -$13.51M derived: sum of 2 quarters · filed 2020-05-07 | -$20.62M derived: sum of 3 quarters · filed 2020-05-07 | -$26.59M derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | -$7.35M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$14.46M derived: sum of 2 quarters · filed 2020-03-16 | -$20.44M derived: sum of 3 quarters · filed 2020-03-16 | -$25.58M 10-K · filed 2020-03-16 |
| 2018-09-30 | -$7.11M 10-Q · filed 2019-11-14 | -$13.09M derived: sum of 2 quarters · filed 2019-11-14 | -$18.22M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | -$5.98M 10-Q · filed 2019-08-12 | -$11.11M 10-Q · filed 2019-08-12 | ||
| 2018-03-31 | -$5.14M 10-Q · filed 2019-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |